INTRODUCTION: Ibogaine is a naturally occurring indole alkaloid with suggested therapeutic potential across substance use disorders, trauma-related conditions, mood disorders, and suicidality. However, its clinical translation has been hindered by safety concerns, regulatory barriers, and uncertainty regarding its complex pharmacology. Recent interest has surged in developing ibogaine analogs...
Background: Opioid use disorder remains a major public health and healthcare-system challenge in Tennessee, where many adults remain untreated, undertreated, or poorly retained in care. Medically monitored ibogaine has been proposed as a potential intervention for OUD, but its economic implications in a state treatment environment have not been well characterized. We evaluated the health and...
The Michigan Society of Addiction Medicine (MiSAM) has written a letter to the Michigan legislature opposing bill HB 6020, which would use opioid settlement funds to expand research into ibogaine.
Iboga alkaloids, including ibogaine, its primary metabolite noribogaine, and the naturally occurring congener ibogamine, have shown promise for the treatment of substance use and other neuropsychiatric disorders but are limited by cardiotoxic effects. Safer synthetic analogs, such as oxa-noribogaine, are under active development; however, validated analytical methods for quantifying these...
Abstract Ibogaine has shown early therapeutic promise for substance use disorders (SUD) and post-traumatic stress disorder in veterans, but concerns about treatment-associated cardiac arrhythmia and death have constrained clinical development. Whether this risk is uniform across indications or concentrated in specific populations is unknown. We conducted a retrospective multisite study of...
Background: Traumatic brain injury (TBI) can result in prolonged post-concussive syndrome and chronic hypoxic-ischemic brain injury (HIBI) sequelae remains therapeutically challenging with the persistence of significant neurological and cognitive impairments. While conventional treatments often provide limited relief, emerging research explores alternative therapeutic interventions, including...
A ibogaína é um alcaloide indólico extraído da Tabernanthe iboga, investigado por seu possível papel na redução de sintomas de abstinência, fissura e recaída em transtornos por uso de substâncias. Este estudo teve como objetivo analisar, por meio de revisão de literatura, as evidências científicas sobre eficácia, segurança, mecanismos farmacológicos e implicações ético-regulatórias do uso da...
Opioid dependence is a public health concern in New Zealand, with limited treatment options beyond opioid substitution therapy (OST). Ibogaine, a psychoactive alkaloid with reported anti-withdrawal and anti-craving effects for opioid dependence, is legally available by prescription in New Zealand, offering a context for exploring user experiences. A qualitative collective case study design was...
Psychedelics have emerged as powerful modulators of neural plasticity, yet whether the atypical psychedelic ibogaine can enhance plasticity remains poorly understood. Here, we investigated whether a single administration of ibogaine can reinstate juvenile-like experience-dependent plasticity in the adult mouse visual cortex, a canonical model for studying neuroplasticity. Adult mice were...
BACKGROUND: Preliminary evidence examining ibogaine in neuropsychiatric and substance use disorders is accumulating. As patient interest and off-label use grow, clinicians require an understanding of emerging dosing strategies, investigational protocols, and reported adverse effects to appropriately counsel patients and contextualize potential risks and benefits. METHODS: Databases were...